Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics intended to enhance regulatory T cell (Treg) function,
announces that Chairman and CEO Howard Berman, Ph.D. has been
recognized as a PharmaVoice 100 winner in the category of Biotech
Pathfinders. The annual list recognizes the most inspiring people
in the life sciences industry and is a another recognition of Dr.
Berman’s impact as Coya’s CEO as he prepares for his transition to
Executive Chairman beginning Nov. 1, as was previously
announced.
“Howard is an incredible founder, businessman, and entrepreneur
whose leadership has built Coya Therapeutics from a small startup
to the clinical-stage company that it is today with numerous
candidates that have the potential to make a serious difference for
those suffering from neurodegenerative diseases,” said Arun
Swaminathan, Ph.D. currently Coya’s Chief Business Officer and
incoming CEO. “This award recognizes Howard and his significant
accomplishments in the life science industry.”
PharmaVoice 100 honorees are selected from a pool of nominations
submitted by readers and colleagues, evaluated by the PharmaVoice
team, and then categorized into 10 distinct groups: Standout
Leaders, Cancer Care Visionaries, Cardiometabolic All-Stars,
Trailblazers, Biotech Pathfinders, Rare Disease Warriors, Tech and
AI Wizards, Clinical Trial Pros, Patient Champions, and Cell and
Gene Therapy Pioneers. Each winner represents the transformative
impact of the pharmaceutical industry in their own unique way.
“These honorees are inspirations. Their teams look to them for
guidance, their patients for support, and their organizations for
direction. Each winner represents progress toward a healthier
future for everyone that is bolstered by science and technological
advancements. We are excited to recognize their contributions
through this annual list,” said Meagan Parrish, lead editor of
PharmaVoice.
Since 2005, the PharmaVoice 100 has become one of the
publication’s most anticipated features. From academia and
nonprofits to Big Pharma, startups, and tech companies, it is the
only awards program in the industry that honors individuals from
all sectors of life sciences. These honorees, from the clinic to
the C-suite, are making meaningful contributions to their fields
and striving to improve outcomes for patients around the world.
About PharmaVoice
PharmaVoice is a leading industry publication operated by
Industry Dive. Our stories deliver the most important voices and
ideas in the life sciences to industry leaders.
About Industry Dive
Industry Dive, an Informa business, is a leading business
journalism company. Over 14 million decision-makers across 20+
competitive industries rely on our exclusive insight and analysis
delivered through more than 30 publications.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions, including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system.
Coya’s investigational product candidate pipeline leverages
multiple therapeutic modalities aimed at restoring the
anti-inflammatory and immunomodulatory functions of Tregs. Coya’s
therapeutic platforms include Treg-enhancing biologics,
Treg-derived exosomes, and autologous Treg cell therapy.
COYA 302 – the Company’s lead biologic investigational product
or “Pipeline in a Product” – is a proprietary combination of COYA
301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous
administration with a unique dual mechanism of action that is now
being developed for the treatment of Amyotrophic Lateral Sclerosis,
Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s
Disease. Its multi-targeted approach enhances the number and
anti-inflammatory function of Tregs and simultaneously lowers the
expression of activated microglia and the secretion of
pro-inflammatory mediators. This synergistic mechanism may lead to
the re-establishment of immune balance and amelioration of
inflammation in a sustained and durable manner that may not be
achieved by either low-dose IL-2 or CTLA4-Ig alone.
For more information about Coya, please visit
www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements.
Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but
not limited to, those related to risks associated with the impact
of COVID-19; the success, cost and timing of our product candidate
development activities and ongoing and planned clinical trials; our
plans to develop and commercialize targeted therapeutics; the
progress of patient enrollment and dosing in our preclinical or
clinical trials; the ability of our product candidates to achieve
applicable endpoints in the clinical trials; the safety profile of
our product candidates; the potential for data from our clinical
trials to support a marketing application, as well as the timing of
these events; our ability to obtain funding for our operations;
development and commercialization of our product candidates; the
timing of and our ability to obtain and maintain regulatory
approvals; the rate and degree of market acceptance and clinical
utility of our product candidates; the size and growth potential of
the markets for our product candidates, and our ability to serve
those markets; our commercialization, marketing and manufacturing
capabilities and strategy; future agreements with third parties in
connection with the commercialization of our product candidates;
our expectations regarding our ability to obtain and maintain
intellectual property protection; our dependence on third party
manufacturers; the success of competing therapies or products that
are or may become available; our ability to attract and retain key
scientific or management personnel; our ability to identify
additional product candidates with significant commercial potential
consistent with our commercial objectives; and our estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241008375457/en/
Investor David Snyder, CFO
david@coyatherapeutics.com
CORE IR Bret Shapiro brets@coreir.com 561-479-8566
Media Kati Waldenburg
media@coyatherapeutics.com 212-655-0924
Coya Therapeutics (NASDAQ:COYA)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Coya Therapeutics (NASDAQ:COYA)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
